PathXL, a Queen’s University Belfast firm developing digital pathology technology, is to create 32 jobs over the next three years.

The firm, which is investing £3.6m into job creation, is looking to drive the expansion of the Northern Ireland-based company with increased sales of its TissueMark software, designed to detect tumours.

Des Speed, PathXL’s CEO, said: “Our ultimate aim is to become world famous for contributing something really meaningful to the field of digital pathology. This investment will help us…